Correspondence (letter to the editor): Need for advice

Comment

Guido Grass et al. Dtsch Arztebl Int. 2010 Sep.

. 2010 Sep;107(38):672; author reply 673-4.

doi: 10.3238/arztebl.2010.0672. Epub 2010 Sep 24.

No abstract available

Comment on

The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.
Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. Schott G, et al. Dtsch Arztebl Int. 2010 Apr;107(16):279-85. doi: 10.3238/arztebl.2010.0279. Epub 2010 Apr 23. Dtsch Arztebl Int. 2010. PMID: 20467553 Free PMC article.
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.
Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig WD. Schott G, et al. Dtsch Arztebl Int. 2010 Apr;107(17):295-301. doi: 10.3238/arztebl.2010.0295. Epub 2010 Apr 30. Dtsch Arztebl Int. 2010. PMID: 20490338 Free PMC article.

1. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences: Part 1. A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int. 2010;107(16):279–285. - PMC - PubMed
1. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences: Part 2. A qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int. 2010;107(17):295–301. - PMC - PubMed